Trial Profile
A Large-scale Multicenter Phase II Study Evaluating the Protective Effect of a Tissue Selective Estrogen Complex (TSEC) in Women With Newly Diagnosed Ductal Carcinoma in Situ
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Conjugated estrogens/bazedoxifene (Primary)
- Indications Breast cancer; Ductal carcinoma; Postmenopause
- Focus Biomarker; Therapeutic Use
- Acronyms PROMISE
- 06 Feb 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 30 Apr 2021 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.
- 30 Apr 2021 Planned primary completion date changed from 1 Aug 2021 to 1 Aug 2022.